MapLight (MPLT) CEO Christopher Kroeger Sells Shares

What Happened

• Christopher A. Kroeger, CEO of MapLight Therapeutics (MPLT), reported multiple open-market sales of company stock executed July 15–17, 2026. Over three days he disposed of a total 147,639 shares for aggregate proceeds of approximately $5,443,723.
• Daily breakdown:
  • July 15: 61,778 shares sold (18,950 @ $36.00 = $682,200; 42,738 @ $36.99 = $1,580,879; 90 @ $37.54 = $3,379) — total ~$2,266,458.
  • July 16: 69,082 shares sold (40,899 @ $36.46 = $1,491,178; 28,091 @ $37.26 = $1,046,671; 92 @ $37.96 = $3,492) — total ~$2,541,341.
  • July 17: 16,779 shares sold (16,779 @ $37.90 = $635,924) — total ~$635,924.
• These were sales (code S). Some of the sales were mandatory "sell-to-cover" transactions to satisfy tax withholding on RSU vesting (see footnote F1); others were open-market disposals.

Key Details

• Transaction dates: July 15–17, 2026. Filing date: July 17, 2026 (appears timely under Form 4 rules).
• Total shares sold: 147,639; total proceeds: ~$5.44 million.
• Prices reported as weighted averages in several line items; reported price ranges in the filing:
  • $35.5338–$36.5273 (F2)
  • $36.53–$37.405 (F3)
  • $35.9075–$36.9013 (F4)
  • $36.9082–$37.89 (F5)
  • $37.49–$37.925 (F6)
• Footnote F1: at least some shares were sold to cover statutory tax withholding for RSU vesting (sell-to-cover), not discretionary sales.
• Footnote F7: certain shares are held by the C&M Kroeger Nominee Trust; Kroeger is co-trustee with voting and dispositive power.
• Shares owned after the transactions are not provided in the summary here — see the full Form 4 for post-transaction holdings.

Context

• These transactions are sales (often routine or tax-related). The presence of a sell-to-cover footnote indicates at least part of the activity was tied to RSU vesting tax obligations rather than a discretionary signal about company prospects.
• No purchases, option exercises, or gifts are reported in this filing. For full allocation of which sales were discretionary vs. mandatory, or to see exact per-trade prices within the reported ranges, consult the detailed Form 4 or request the breakdown referenced in the filing.